Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient.
The DiFi human colorectal cancer cell line was recently established from a familial adenomatous polyposis patient with extracolonic features characteristic of the Gardner syndrome. These cells have now been propagated for 150 passages in standard culture media and vessels without feeder layers or collagen coatings. They retain features of colonic epithelial cells such as surface microvilli, secretory vesicles, and desmosomes. Cytosol of DiFi cells contains a high level (502 U/mg protein) of the mucin CA 19-9. In addition, DiFi cells produce carcinoembryonic antigen, and induce tumors in athymic mice. Cytoskeleton analysis of DiFi cells by fluorescence microscopy showed a pronounced disorganization of actin cable structure. The isozyme genetic signature of DiFi cells is unique (0.01 probability of finding the same genetic signature in a different cell line), differs from that of HeLa cells, and has expressional features seen in other colorectal cell lines. The DiFi cell karyotype is tetraploid, contains many marker chromosomes, and shows numerous episomal particles. Two copies of chromosome 18 were absent, and only a single normal chromosome 17 was found. This parallels detection of allelic losses from DiFi cell DNA at loci on chromosomes 17p and 18 using molecular (cDNA) probes. DiFi cells clearly express transcripts for the c-myc proto-oncogene, the c-myb proto-oncogene, and the p53 tumor suppressor gene. Transforming growth factor beta inhibits DiFi cell growth in soft agar and suppresses c-myc expression in these cells. The value of this cell line in the study of genetic alterations in colorectal cancer is discussed.
University of Texas M. D. Anderson Cancer Center, Section of Gastrointestinal Oncology and Digestive Diseases, Houston 77030.
M
M
Olive
S
S
Untawale
R J
RJ
Coffey
M J
MJ
Siciliano
D M
DM
Wildrick
H
H
Fritsche
S
S
Pathak
L M
LM
Cherry
M
M
Blick
P
P
Lointier
D000199:Actins / Q000648:ultrastructure; D002288:Adenocarcinoma, Mucinous / Q000235:genetics* / Q000648:ultrastructure; D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D002453:Cell Cycle; D002460:Cell Line / Q000737:chemistry / Q000187:drug effects; D003594:Cytoplasmic Granules / Q000648:ultrastructure; D003896:Desmosomes / Q000648:ultrastructure; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D006801:Humans; D007621:Karyotyping; D051379:Mice; D008819:Mice, Nude; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D000090063:Proto-Oncogene Mas; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D012004:Rectal Neoplasms / Q000235:genetics* / Q000648:ultrastructure; D016212:Transforming Growth Factor beta / Q000494:pharmacology
D000199:Actins; D015295:Antigens, Tumor-Associated, Carbohydrate; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D016271:Proto-Oncogene Proteins c-myc; D016212:Transforming Growth Factor beta